Trial Profile

Randomised, Double-blind, Multi-centre study to compare the the safety, tolerability, and immunogenicity of the refrigerator-stable formulation of the Varicella vaccine to that of the frozen formulation in Healthy children

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 04 Sep 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Varicella zoster virus vaccine live (Primary) ; Measles mumps and rubella virus vaccine
Indications Varicella zoster virus infections
Focus Adverse reactions; Therapeutic Use
Sponsors Merck & Co

04 Sep 2018 New trial record
23 Aug 2018 Primary endpoint (Immune Response) has been met, according to the results published in the Vaccine.
23 Aug 2018 Results published in the Vaccine

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com